Spectrum Pharmaceuticals, Inc. announced that it has entered in equity purchase agreement for the issuance of 12,500,000 common shares at a price of $1.6 per common share for a total gross proceeds of $20,000,000 on January 4, 2022. The transaction will include participation from returning investor Hanmi Pharm. Co., Ltd. The transaction is expected to close on or around January 6, 2022.